ALK mutants bind PI3KCA

Stable Identifier
R-HSA-9712083
Type
Reaction [binding]
Species
Homo sapiens
Compartment
cytosol
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
ALK mutants bind PI3KCA
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
The catalytic subunit of PI3K is recruited downstream ALK fusions and point mutants signal through the PI3K pathway as assessed by both binding and activity assays (Bai et al, 2000; Slupianek and Tomasz, 2001; Slupianek et al, 2004; Koivunen et al, 2008; George et al, 2008; Wang et al, 2011; reviewed in Roskoski, 2013; Hallberg and Palmer, 2013; Della Corte et al, 2018; Ducray et al, 2019).
Literature References
PubMed ID Title Journal Year
11110708 Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway

Ouyang, T, Morris, SW, Bai, RY, Duyster, J, Miething, C, Peschel, C

Blood 2000
29455642 Role and targeting of anaplastic lymphoma kinase in cancer

Troiani, T, Viscardi, G, Morgillo, F, Fasano, M, Martinelli, E, Ciardiello, F, Della Corte, CM, Di Liello, R

Mol. Cancer 2018
31366041 The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis

Ducray, SP, Turner, SD, Garland, GD, Natarajan, K, Egger, G

Cancers (Basel) 2019
21656749 A novel KIF5B-ALK variant in nonsmall cell lung cancer

Leung, EL, Tin, VP, Wong, MP, Au, JS, Cheng, LC, Sihoe, AD, Wong, DW, Chung, LP, Wong, SK

Cancer 2011
18923525 Activating mutations in ALK provide a therapeutic target in neuroblastoma

Zozulya, S, George, RE, Gilliland, DG, Morris, SW, Luther, W, London, WB, Hanna, M, Meyerson, M, McGrady, P, Sanda, T, Gregor, VE, Look, AT, Zhang, J, Fröhling, S, Ahn, Y, Diller, L, Webb, TR, Zhou, W, Greulich, H, Gray, NS, Xue, L

Nature 2008
11280786 Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis

Morrione, A, Xue, L, Hoser, G, Wasik, MA, Slupianek, A, Nieborowska-Skorska, M, Morris, SW, Majewski, M, Skorski, T

Cancer Res 2001
23201355 Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition

Roskoski, R

Pharmacol. Res. 2013
24060861 Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

Palmer, RH, Hallberg, B

Nat. Rev. Cancer 2013
18594010 EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

Koivunen, JP, Murphy, C, Thomas, R, Zejnullahu, K, Jänne, PA, Holmes, AJ, Ducko, C, Sugarbaker, DJ, Lifshits, E, Choi, HG, Chiang, D, Meyerson, M, Engelman, JA, Lee, C, Lindeman, N, Lee, J, Richards, WG, Marcoux, JP, Kim, J, Gray, NS, Mermel, C

Clin Cancer Res 2008
15588951 NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner

Skorski, T, Slupianek, A

Exp. Hematol. 2004
Participants
Input
Output
Participates
as an event of
Normal reaction
Active ALK recruits PI3K (Homo sapiens)
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2021-03-22)
Reviewed
Inghirami, G  (2021-05-04)
Created
Rothfels, K  (2021-01-14)
Cite Us!